London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Paris, France and Camberley, UK – 20 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that its Annual General Meeting
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at
Paris, France and Camberley, UK – 18 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces a half year update in
DeepMatter collaborates with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies
Paris, France and Camberley, UK – 5 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces that it will hold
Paris, France and Camberley, UK – 29 July 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces the appointment of David
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
Transformational performance in 2020 Continued strong demand for COVID-19 testing in 2021
